X-linked ichthyosis

X-linked lymphoproliferative disease

Autosomal recessive agammaglobulinaemia (Swiss type) X-linked agammaglobulinaemia [Bruton] (with growth hormone deficiency)

Early-onset cerebellar ataxia with:essential tremor | myoclonus [Hunt's ataxia] | retained tendon reflexes | Friedreich's ataxia (autosomal recessive) X-linked recessive spinocerebellar ataxia

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

chromosomal | chromosome-related

AAMD - Age related macular degeneration

Early-onset X-linked optic atrophy

An extremely rare mitochondrial respiratory chain disease resulting in a neurodegenerative disorder with characteristics of psychomotor delay, hypotonia, areflexia, muscle weakness and wasting in the two patients reported to date. Combined oxidative

X-linked intellectual disability, nail dystrophy, seizures syndrome

Kurinczuk argued that ICSI enables the inheritance of y-chromosome linked microdeletions, thus increasing the population prevalence of otherwise rare genetic disorders; however, there is a comparatively low risk of y-linked inheritance of abnormalities.

Testing healthy individuals for carrier status for X-linked or autosomal recessive conditions is often considered to be of minimal risk when comparing with testing those who are at risk for adult onset disorders.

In a Phase III study (A2303) in newly diagnosed Ph+ CML patients, atherosclerotic-related diseases such as peripheral arterial occlusive disease, femoral artery stenosis, coronary artery stenosis, carotid artery stenosis, and cerebrovascular accident were reported in patients taking TASIGNA* (5.0% for TASIGNA* 300 mg BID and 6.1% for TASIGNA* 400 mg BID).

In a Phase III study (A2303) in newly diagnosed Ph+ CML patients, atherosclerotic-related diseases such as peripheral arterial occlusive disease, femoral artery stenosis, coronary artery stenosis, carotid artery stenosis, and cerebrovascular accident were reported in patients taking TASIGNA* (5.0% for TASIGNA* 300 mg BID and 6.1% for TASIGNA* 400 mg BID).